Clonal hematopoiesis in sickle cell disease

Area of Science:

• Hematology
• Genetics
• Oncology

Background:

• Sickle cell disease (SCD) patients have a higher risk of myeloid malignancies, but the causes are unclear.
• Clonal hematopoiesis (CH) is a premalignant condition linked to myeloid cancer predisposition.
• The role of CH in SCD-associated cancer risk is not well understood.

Purpose of the Study:

• To investigate the prevalence and characteristics of clonal hematopoiesis (CH) in individuals with sickle cell disease (SCD).
• To determine if CH contributes to the increased risk of myeloid malignancies observed in SCD patients.

Main Methods:

• Utilized whole-genome sequencing data from 74,190 individuals.
• Employed somatic mutation calling methods to identify CH.
• Compared CH rates and clone properties between individuals with and without SCD.

Main Results:

• No significant difference in the rate or clone properties of CH was detected between individuals with SCD and controls.
• Hydroxyurea treatment did not alter the rate of CH in individuals with SCD.
• The study possessed sufficient statistical power to detect a 2-fold increase in CH rate.

Conclusions:

• Individuals with SCD do not exhibit an increased risk of detectable CH based on whole-genome sequencing.
• These findings may help refine risk assessments for myeloid malignancies in SCD patients.
• Understanding CH risk factors is essential for the safe implementation of gene therapies for SCD.